You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 7,612,058

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,612,058

Title:	Methods for inhibiting sterol absorption
Abstract:	The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Inventor(s):	Cho; Wing-Kee Philip (Princeton, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	10/998,400
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,612,058
Patent Claims:	1. A method of treating a vascular condition associated with elevated sterol and/or stanol levels, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00003 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00087## 2. The method according to claim 1, wherein the vascular condition is atherosclerosis. 3. A method of treating diabetes in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00004 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00088## 4. A method of treating obesity in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00005 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00089## 5. A method of lowering a plasma sterol concentration of a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting of: TABLE-US-00006 Weight percent of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00090## 6. A method of treating a vascular condition associated with elevated sterol and/or stanol levels, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00007 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00091## 7. The method according to claim 6, wherein the vascular condition is atherosclerosis. 8. A method of treating diabetes in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00008 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00092## 9. A method of treating obesity in a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00009 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00093## 10. A method of lowering a plasma sterol concentration of a mammal, comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition consisting essentially of: TABLE-US-00010 milligrams of Ingredient ingredient Compound of Formula (II) 10 Lactose monohydrate 55 Microcrystalline cellulose 20 Povidone 4 Croscarmellose sodium 8 Sodium lauryl sulfate 2 Magnesium stearate 1 Total 100 wherein the compound represented by Formula (II) below is: ##STR00094##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.